Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal bevacizumab + propranolol versus bevacizumab alone for neovascular age-related macular degeneration
IRCT20240415061498N1Phase 3Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in exudative macular degeneration comparing Bevacizumab alone with Bevacizumab + propranolol (2 arms). Started Dec 2024; status: completed.
02
Drugs
bevacizumabpropranolol
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on IRCT20240415061498N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240415061498N1.